Transfusion Medicine – Red Cell Biology
We study the biology and formation of the red blood cell and its polymorphic surface molecules, specifically the role of blood groups in health and disease. Our group has a strong and longstanding track record in the discovery and characterization of these molecules, the compatibility of which is crucially important for both safe blood transfusions, solid organ transplantation and the fetomaternal relationship during pregnancy. Research from our group has laid the foundation for five new blood group systems so far and for two of them (SMIM1/VEL and EMP3/MAM) we are now exploring their role as regulators of erythropoiesis, from stem cell to mature red cell.
We strive to understand the molecular genetics, structure, and function of erythroid surface molecules, in order to explain how early steps during erythropoiesis are regulated. By doing so, our long-term vision is to open up new therapeutic avenues beyond blood transfusion and erythropoietin (Epo) to treat anemia. We also envision novel erythroid targets for pharmaceutical intervention in thrombotic disease.
- To discover and characterize new blood groups
- To unravel the hidden regulators of early erythropoiesis
- To explore the emerging role of erythrocytes in hemostasis
Anemia is a common condition that affects a large proportion of people worldwide. According to WHO, close to 120 million blood donations are made around the globe annually to help patients survive acute blood loss following trauma, surgery and obstetrical complications. Yet other patient categories rely on safe blood for cancer treatment, hemoglobinopathies and to support stem cell transplantation. However, today the therapeutic alternatives to treat anemia, beyond nutritional aspects, are surprisingly few.
Our main mission is to improve current blood selection practices and develop alternatives to traditional transfusion therapy, including interference with regulators of erythropoiesis and culture of stem and progenitor cells towards mature red cells. Furthermore, defining an active role for erythroid cells in hemostasis has potential impact for patients suffering from thrombotic disease like stroke and myocardial infarction, if anticoagulants could target not only platelets and coagulation factors but also our most common cell.
Principal Investigator, Martin_L [dot] Olsson [at] med [dot] lu [dot] se
Associate Professor, Jill [dot] Storry [at] med [dot] lu [dot] se
Lab Manager, Maria [dot] Allhorn [at] med [dot] lu [dot] se
PhD student & lab engineer, Abdul_Ghani [dot] Alattar [at] med [dot] lu [dot] se
PhD student, Gloria [dot] Wu [at] med [dot] lu [dot] se
PhD student, Anja [dot] Nylander [at] med [dot] lu [dot] se
Research Administrator, Ann-Marie [dot] Lenndin [at] med [dot] lu [dot] se
MARTIN L. OLSSON
MD, PhD, Professor
Division of Hematology and Transfusion Medicine
Department of Laboratory Medicine
Lund Stem Cell Center
BMC C14, Lund University
221 84 Lund, Sweden
Phone: + 46 46 222 32 07
- Lund Stem Cell Center
- EpiHealth (board member)
- Center for Translational Genomics (CTG; chair of the board)
- Center for Translational Proteomics (CTP) and national infrastructure BioMS (member of steering committee)
- Clinical Immunology and Transfusion Medicine, Medical Service, Region Skåne
- International Society of Blood Transfusion (Past President)